<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00147316</url>
  </required_header>
  <id_info>
    <org_study_id>527-0110</org_study_id>
    <nct_id>NCT00147316</nct_id>
  </id_info>
  <brief_title>Japan Alteplase Clinical Trial (J-ACT): Efficacy and Safety Study of Tissue Plasminogen Activator (Alteplase) for Ischemic Stroke</brief_title>
  <official_title>Japan Alteplase Clinical Trial (J-ACT): Phase 3 Efficacy and Safety Study of Tissue Plasminogen Activator (Alteplase) for Acute Ischemic Stroke Within 3 Hours of Onset</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mitsubishi Tanabe Pharma Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kyowa Hakko Kogyo Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mitsubishi Tanabe Pharma Corporation</source>
  <brief_summary>
    <textblock>
      Based on previous studies comparing Duteplase[a recombinant tissue plasminogen activator
      (rt-PA) very similar to alteplase] doses, we performed a clinical trial with 0.6mg/kg, which
      is lower than the internationally approved dosage of 0.9mg/kg, aiming to assess the efficacy
      and safety of alteplase for the Japanese.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Based on previous studies comparing Duteplase ( an rt-PA very similar to alteplase) doses, we
      performed a clinical trial with 0.6mg/kg, which is lower than the internationally approved
      dosage of 0.9mg/kg, aiming to assess the efficacy and safety of alteplase for the Japanese.

      The primary endpoints were the rate of patients with mRS score of 0-1 at 3 months and the
      incidence of sICH within 36 hours. Thresholds for these endpoints were determined by
      calculating 90% confidence intervals of weighted averages derived from published reports. The
      protocol was defined according to the National Institute of Neurological Disorders and Stroke
      (NINDS) rt-PA stroke study with slight modifications.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2002</start_date>
  <completion_date>September 2003</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With a Modified Rankin Scale (mRS) Score of 0-1 at 3 Months</measure>
    <time_frame>at 3 months</time_frame>
    <description>The number of patients with a mRS score of 0-1. The mRS has 6 items, where 0 = No symptoms at all, 1 = No significant disability despite symptoms, 2 = Slight disability, 3 = Moderate disability, 4 = Moderately severe disability, 5 = Severe disability. The higher scores reflect increased disability.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients With Symptomatic Intracranial Hemorrhage (sICH) Within 36 Hours</measure>
    <time_frame>within 36 hours</time_frame>
    <description>The number of patients with sICH</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">103</enrollment>
  <condition>Cerebral Infarction</condition>
  <condition>Brain Ischemia</condition>
  <arm_group>
    <arm_group_label>Alteplase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.6mg/kg intravenous alteplase with 10% being administered as a bolus followed by continuous infusion of the remainder over 1 hour</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alteplase</intervention_name>
    <description>0.6mg/kg intravenous alteplase with 10% being administered as a bolus followed by continuous infusion of the remainder over 1 hour</description>
    <arm_group_label>Alteplase</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients with acute ischemic stroke within 3 hours of onset, with a clearly defined time of
        onset

        Exclusion Criteria:

          1. patients with rapidly improving neurological symptoms or with minor neurological
             deficit (National Institutes of Health Stroke Scale (NIHSS) score of ≤4) prior to the
             start of treatment

          2. Computed Tomography (CT) evidence of non-minor early ischemic signs (minor early
             ischemic sign was defined as the involvement of one-third or less of the middle
             cerebral artery area)

          3. CT evidence of cerebral hemorrhage or subarachnoid hemorrhage

          4. symptoms suggestive of subarachnoid hemorrhage

          5. lactation, pregnancy or suggestive pregnancy; menstruation

          6. platelet count below 100,000/mm3

          7. heparin administration within 48 hours preceding stroke onset with an elevated
             activated partial thromboplastin time (APTT); current use of oral anticoagulants with
             an International Normalized Ratio (INR) of ≥1.7; use of drugs not allowed to be
             administered concomitantly with alteplase (other thrombolytic agents, ozagrel sodium,
             argatroban and edaravone) prior to the study treatment

          8. major surgery or serious trauma within the preceding 14 days; serious head or spinal
             cord trauma within the preceding 3 months

          9. a history of gastrointestinal or urinary tract hemorrhage within the previous 21 days

         10. arterial puncture at a noncompressible site within the preceding 7 days

         11. a history of stroke within the preceding 3 months; a history of intracranial
             hemorrhage or increased risk of intracranial hemorrhage because of cerebral aneurysm,
             arteriovenous malformation, neoplasm, etc.

         12. concurrent severe hepatic or renal dysfunction

         13. malignant tumor under treatment

         14. a systolic blood pressure of &gt;185 mmHg or diastolic blood pressure of &gt;110 mmHg

         15. a need for aggressive treatment to reduce blood pressure to below these limits(14))

         16. blood glucose levels of &lt;50 mg/dL or &gt;400 mg/dL

         17. acute myocardial infarction(AMI) or endocarditis after AMI

         18. concurrent infectious endocarditis, moya-moya disease (Willis circle occlusion
             syndrome), aortic dissection, neck trauma, etc.; strong suspicion of ischemic
             cerebrovascular disorder caused by non-thrombotic occlusion or any other hemodynamic
             condition

         19. seizure at the onset of stroke

         20. coma (a Japan Coma Scale score of ≥100)

         21. an mRS score of ≥2 before stroke onset

         22. a history of hypersensitivity to protein preparations

         23. difficulty in monitoring for 3 months

         24. less than 3 months since any other clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Takenori Yamaguchi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>National Cerebral and Cardiovascular Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Cardiovascular Center</name>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <zip>565-8565</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <results_reference>
    <citation>Yamaguchi T, Mori E, Minematsu K, Nakagawara J, Hashi K, Saito I, Shinohara Y; Japan Alteplase Clinical Trial (J-ACT) Group. Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT). Stroke. 2006 Jul;37(7):1810-5. Epub 2006 Jun 8.</citation>
    <PMID>16763187</PMID>
  </results_reference>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 5, 2005</study_first_submitted>
  <study_first_submitted_qc>September 5, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2005</study_first_posted>
  <results_first_submitted>January 19, 2012</results_first_submitted>
  <results_first_submitted_qc>January 19, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 24, 2012</results_first_posted>
  <last_update_submitted>February 29, 2012</last_update_submitted>
  <last_update_submitted_qc>February 29, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 1, 2012</last_update_posted>
  <keyword>acute stroke</keyword>
  <keyword>thrombolytic therapy</keyword>
  <keyword>tissue plasminogen activator</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Brain Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Plasminogen</mesh_term>
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Alteplase</title>
          <description>0.6mg/kg intravenous alteplase with 10% being administered as a bolus followed by continuous infusion of the remainder over 1 hour</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="103"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="103"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Alteplase</title>
          <description>0.6mg/kg intravenous alteplase with 10% being administered as a bolus followed by continuous infusion of the remainder over 1 hour</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="103"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.9" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With a Modified Rankin Scale (mRS) Score of 0-1 at 3 Months</title>
        <description>The number of patients with a mRS score of 0-1. The mRS has 6 items, where 0 = No symptoms at all, 1 = No significant disability despite symptoms, 2 = Slight disability, 3 = Moderate disability, 4 = Moderately severe disability, 5 = Severe disability. The higher scores reflect increased disability.</description>
        <time_frame>at 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Alteplase</title>
            <description>0.6mg/kg intravenous alteplase with 10% being administered as a bolus followed by continuous infusion of the remainder over 1 hour</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With a Modified Rankin Scale (mRS) Score of 0-1 at 3 Months</title>
          <description>The number of patients with a mRS score of 0-1. The mRS has 6 items, where 0 = No symptoms at all, 1 = No significant disability despite symptoms, 2 = Slight disability, 3 = Moderate disability, 4 = Moderately severe disability, 5 = Severe disability. The higher scores reflect increased disability.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Symptomatic Intracranial Hemorrhage (sICH) Within 36 Hours</title>
        <description>The number of patients with sICH</description>
        <time_frame>within 36 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Alteplase</title>
            <description>0.6mg/kg intravenous alteplase with 10% being administered as a bolus followed by continuous infusion of the remainder over 1 hour</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Symptomatic Intracranial Hemorrhage (sICH) Within 36 Hours</title>
          <description>The number of patients with sICH</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 Months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Alteplase</title>
          <description>0.6mg/kg intravenous alteplase with 10% being administered as a bolus followed by continuous infusion of the remainder over 1 hour</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>5.0</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Cardiac failure NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Pneumonia NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Brain herniation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Tracheal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Traumatic haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Left atrial myxoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Metastases to peritoneum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Brain oedema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Carotid artery dissection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Haemorrhagic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Intracranial haemorrhage NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Subdural hygroma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Renal impairment NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma aggravated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Atherosclerosis obliterans</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>5.0</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="91" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea NOS</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage NOS</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Periproctitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Vomiting NOS</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic function abnormal NOS</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia NOS</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Urinary tract infection NOS</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhagic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Headache NOS</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Neurogenic bladder</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhage subcutaneous</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trials, Information Desk</name_or_title>
      <organization>Mitsubishi Tanabe Pharma Corporation</organization>
      <email>cti-inq-ml@ml.mt-pharma.co.jp</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

